Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises D. Carnegie & Co in connection with Blackstone’s mandatory offer
Mandate

Vinge advises D. Carnegie & Co in connection with Blackstone’s mandatory offer

October 27, 2016

Vinge has advised D. Carnegie & Co AB (publ) (“D. Carnegie & Co”) in connection with a mandatory offer to the shareholders and warrant holders of D. Carnegie & Co, made by Blackstone through Vega Holdco S.à r.l. (”Vega Holdco”). Vega Holdco offers SEK 100 in cash per A- and B-share in D. Carnegie & Co. Based on all outstanding shares and warrants in the company, the total value of D. Carnegie & Co amounts to approximately SEK 7.8 billion.

Vinge’s team primarily consisted of Jesper Schönbeck, David Andersson and Sofie Bjärtun.

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025